Abecma - Multiple Myeloma - MAR Display Banners HCP Wallboard Extension - 623660 - Physician's Weekly


Advertisement

Abecma – Multiple Myeloma – MAR Display Banners HCP Wallboard Extension – 623660

Second-Line Therapies Continue to Evolve

Multiple myeloma (MM) treatment has evolved significantly since 2000, fueled by the approval of new agents as well as the precision medicine movement that is the mantra of clinical medicine, regardless of disease. Although there...

High Natural Killer Count Is Predictor of MRD-Negativity

For patients with multiple myeloma (MM) who are treated with autologous stem cell transplantation (ASCT), high absolute natural killer (NK) cell counts 2 to 3 months after ASCT are an independent predictor for minimal residual...

Fall Risk-Increasing Drug Use High in Older Adults With MM

The frequency of fall riskincreasing drug (FRID) use is high in older adults with multiple myeloma (MM) and is positively associated with polypharmacy, according to a study published in the Journal of Geriatric Oncology. Adriano...

Loading

Advertisement

For latest news and updates
Email-id is invalid